IPSC vs VOR
IPSC: Century Therapeutics is an innovative biotechnology firm developing off-the-shelf, gene-edited iPSC-derived cell therapies to cure cancer and autoimmune diseases. VOR: Vor Biopharma is a clinical-stage biopharmaceutical company developing advanced cell therapy and gene therapy solutions for blood disorders and cancers.
Side-by-side fundamentals
| Metric | IPSC | VOR | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.15 | $19.51 | |
| Market cap as of 2026-07-23 | $388M | $1.1B | |
| PEG as of 2026-07-23 | -0.01 | -0.00 | IPSC lower |
| Net margin as of 2026-07-23 | -18.9% | n/a | |
| Operating margin as of 2026-07-23 | -28.6% | n/a | |
| ROE as of 2026-07-23 | -53.2% | -142.1% | IPSC higher |
| ROA as of 2026-07-23 | -39.9% | -261.2% | IPSC higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | +175.9% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +175.9% | n/a | |
| Beta as of 2026-07-23 | 1.58 | 1.60 | |
| 1-year return as of 2026-07-22 close | +289.6% | -51.1% | IPSC higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.